Low serum paraoxonase: a risk factor for atherosclerotic disease?
Serum paraoxonase (PON1) hydrolyses organophosphate (OP) insecticides and nerve gases and is responsible for determining the selective toxicity of these compounds in mammals. PON1 has two genetic polymorphisms giving rise to amino acid substitutions at position 55 and 192. The 192 polymorphism is the major determinant of the PON1 activity polymorphism towards organophosphates. However, the 55 polymorphism also modulates activity. PON1 also may be a determinant of resistance to the development of atherosclerosis by protecting lipoproteins against oxidative modification perhaps by hydrolysing phospholipid-hydroperoxides. The PON1 polymorphisms are important in determining the capacity of high-density lipoprotein (HDL) to protect low-density lipoprotein (LDL) against oxidative modification in vitro and this may explain the relationship between the PON1 alleles and coronary heart disease in case-control studies.
University Department of Medicine, Manchester Royal Infirmary, UK.
M I
MI
Mackness
P N
PN
Durrington
A
A
Ayub
B
B
Mackness
D000818:Animals; D001161:Arteriosclerosis / Q000201:enzymology* / Q000235:genetics; D043303:Aryldialkylphosphatase; D004950:Esterases / Q000097:blood* / Q000235:genetics; D006801:Humans; D011110:Polymorphism, Genetic; D012307:Risk Factors
D004950:Esterases; D043303:Aryldialkylphosphatase; C468406:PON1 protein, human